Monday brought fresh optimism from Wall Street as several top analysts initiated coverage on companies across the biotech and technology sectors. All five initiations came with Buy ratings, suggesting analysts see meaningful upside potential from current trading levels.

BlackSky Technology Leads With Ambitious Target

Blacksky Technology Inc (BKSY) drew attention from Jefferies with a Buy rating and a $23 price target. With shares closing at $19.25 on Friday, that implies roughly 19% upside for the space-based intelligence and imagery company.

Biotech Names Draw Multiple Initiations

The biotech sector captured most of the analyst action. BTIG analyst Thomas Shrader launched coverage on Invivyd Inc (IVVD) with a Buy rating and $10 price target. That represents substantial upside from Friday's closing price of $2.30—a more than 300% gain if the target proves accurate.

Jefferies analyst Farzin Haque initiated coverage on Relmada Therapeutics Inc (RLMD) with a Buy rating and $9 price target. The stock closed Friday at $4.35, putting the target roughly 107% above current levels.

Jones Trading analyst Soumit Roy began coverage on Context Therapeutics Inc (CNTX) with a Buy rating and $7 price target. Context shares finished Friday's session at $1.27, suggesting the analyst sees potential for a roughly 450% rally.

Climate Tech Gets The Nod

Rounding out Monday's initiations, LUCID CAPITAL MARKETS analyst Alex Fuhrman started coverage on AirJoule Technologies Corp (AIRJ) with a Buy rating and $7 price target. AirJoule shares closed at $3.35 on Friday, implying potential upside of about 109%.

The simultaneous bullish calls across multiple sectors suggest analysts are identifying opportunities in smaller-cap names where they see catalysts that could drive significant appreciation. Whether these optimistic price targets materialize will depend on execution from the companies and broader market conditions, but for now, Wall Street is voting with confidence.